Active substance
Hepatitis b virus hbsag surface antigen
- SFDA 7
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ENGERIX B | 20 µg | Suspension for injection · Intramuscular use | 1 Vial | SAR 42.50 | Biological · Prescription | GLAXO SAUDI ARABIA | Valid |
| ENGERIX-B | 10 µg | Suspension for injection · Intramuscular use | 1 Vial | SAR 30.90 | Biological · Prescription | GLAXO SAUDI ARABIA | Valid |
| EUVAX B 10MCG VIAL | 10 µg | Suspension for injection · Intramuscular use | 10 Vial | SAR 374.35 | Biological · Prescription | ARAB COMPANY FOR PHARMACEUTICAL PRODUCTS (ARABIO) | Valid |
| EUVAX B 20MCG VIAL | 20 µg | Suspension for injection · Intramuscular use | 10 Vial | SAR 582.40 | Biological · Prescription | ARAB COMPANY FOR PHARMACEUTICAL PRODUCTS (ARABIO) | Valid |
| Engerix B 20 | 20 µg | Suspension for injection · Intramuscular use | 1 Pre-filled syringe | SAR 66.90 | Biological · Prescription | Glaxo Saudi Arabia Ltd. | Valid |
| Engerix-B10 | 10 µg | Suspension for injection · Intramuscular use | 1 Pre-filled syringe | SAR 42.45 | Biological · Prescription | Glaxo Saudi Arabia Ltd | Valid |
| RECOMBIVAX HB | Suspension for injection · Intramuscular use | 1 Vial | SAR 40.45 | Biological · Prescription | MERCK SHARP AND DOHME LLC | Valid |
Indications — CHI Daman Drug Formulary
ADULT IMMUNIZATION; MATERNAL AND CHILD HEALTHCARE- IMMUNIZATION FOR MOTHER AND CHILD; RENAL TRANSPLANT; TRAVEL IMMUNIZATION
Combinations containing Hepatitis b virus hbsag surface antigen
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.